JINARC^® Prescription Medicine (tolvaptan tablets). JINARC^® is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 4 at initiation of treatment with evidence of rapidly progressing disease. Before prescribing JINARC, please refer to the full Data Sheet for information on dosage, contraindications, precautions, interactions and adverse effects. Because of the risk of liver injury, prescriber education and certification on the risk of liver injury and the importance of regular liver function monitoring is mandatory. These are available through the IMADJIN^® Program, which is run and maintained by, or for, Otsuka Australia Pharmaceutical Pty. Ltd. Further information on the IMADJIN^® Program is available at www.jinarc.co.nz or by telephone at 0800 602 200. Date of Preparation of TAPS Mandatories: 23 Sep 2022

JINARC is a funded medicine subject to the restrictions of the Special Authority prescribing and patient eligibility criteria. Review full Data Sheet before prescribing. Approved Data Sheet is available from Otsuka Australia Pharmaceutical Pty Ltd Ph 0800 602 200 or at https://www.medsafe.govt.nz/Profs/Datasheet/j/jinarctabcomb.pdf.